M Anthony Moody

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4258529/m-anthony-moody-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

171	10,203	59	97
papers	citations	h-index	g-index
179	12,449	11.1 avg, IF	5.46
ext. papers	ext. citations		L-index

#	Paper	IF	Citations
171	Age-related changes in the nasopharyngeal microbiome are associated with SARS-CoV-2 infection and symptoms among children, adolescents, and young adults <i>Clinical Infectious Diseases</i> , 2022 ,	11.6	2
170	InfantsRdiminished response to DTaP vaccine is associated with exposure to organophosphate esters <i>Science of the Total Environment</i> , 2022 , 837, 155782	10.2	1
169	Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2875-e2	.45 .882	34
168	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s Frontiers in Immunology, 2021 , 12, 787603	8.4	
167	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	15
166	Vaccine Development: Steps to Approval of an Investigational Vaccine. <i>North Carolina Medical Journal</i> , 2021 , 82, 141-144	0.6	
165	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021 , 184, 2955-2972.e25	56.2	22
164	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021 , 12, 678511	8.4	4
163	Differential immune imprinting by influenza virus vaccination and infection in nonhuman primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	2
162	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021 , 17, e1009624	7.6	
161	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021 , 371,	33.3	22
160	The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates 2021 ,		27
159	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth. <i>Scientific Reports</i> , 2021 , 11, 14494	4.9	2
158	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021 , 184, 4203-4219.e32	56.2	89
157	Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. <i>JCI Insight</i> , 2021 , 6,	9.9	15
156	Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques <i>PLoS ONE</i> , 2021 , 16, e0256885	3.7	
155	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. <i>Npj Vaccines</i> , 2020 , 5, 36	9.5	5

(2018-2020)

154	Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. <i>MBio</i> , 2020 , 11,	7.8	15
153	Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. <i>MSphere</i> , 2020 , 5,	5	1
152	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020 , 11, 948	17.4	9
151	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020 , 30, 1553-1569.e6	10.6	10
150	Innovations in HIV-1 Vaccine Design. Clinical Therapeutics, 2020, 42, 499-514	3.5	11
149	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. <i>Nature Immunology</i> , 2020 , 21, 199-209	19.1	22
148	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020 , 94,	6.6	13
147	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. <i>JCI Insight</i> , 2020 , 5,	9.9	11
146	SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study 2020 ,		15
145	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. <i>MBio</i> , 2020 , 11,	7.8	2
144	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019 , 50, 677-691.e13	32.3	38
143	Right-sided endocarditis from in a patient with tetralogy of Fallot. <i>Gastroenterology Insights</i> , 2019 , 11, 7872	2.1	2
142	Influenza and Antibody-Dependent Cellular Cytotoxicity. Frontiers in Immunology, 2019, 10, 1457	8.4	33
141	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. <i>Scientific Reports</i> , 2019 , 9, 10165	4.9	4
140	Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 168-173	11.5	80
139	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018 , 92,	6.6	25
138	Functional interrogation and mining of natively paired human V:V antibody repertoires. <i>Nature Biotechnology</i> , 2018 , 36, 152-155	44.5	80
137	Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59 -adjuvanted pandemic 2009 H1N1 vaccine. <i>Vaccine</i> , 2018 , 36, 5325-5332	4.1	2

136	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018 , 215, 1571-1588	16.6	212
135	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2018 , 92,	6.6	27
134	Strength through Organization: Classifying Antibody Activity against EBOV. <i>Cell Host and Microbe</i> , 2018 , 24, 185-186	23.4	
133	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. <i>Nature Communications</i> , 2018 , 9, 2363	17.4	24
132	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , 2018 , 25, 3123-3135.e6	10.6	17
131	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018 , 49, 1162-1174.e8	32.3	32
130	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. <i>Cell</i> , 2018 , 175, 387-399.e17	56.2	42
129	Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women. <i>Vaccine</i> , 2018 , 36, 6354-6360	4.1	18
128	Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. <i>Immunological Reviews</i> , 2017 , 275, 62-78	11.3	37
127	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. <i>Journal of Immunology</i> , 2017 , 198, 1047-1055	5.3	5
126	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. <i>Journal of Virology</i> , 2017 , 91,	6.6	30
125	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017 , 2,	28	86
124	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017 , 18, 2175-2188	10.6	50
123	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017 , 8, 15711	17.4	94
122	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	127
121	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	59
120	Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission. <i>Vaccine Journal</i> , 2017 , 24,		9
119	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017 , 8, 1732	17.4	52

118	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. <i>Vaccine Journal</i> , 2017 , 24,		22
117	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with	6.6	16
116	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. <i>Journal of Virology</i> , 2017 , 91,	6.6	12
115	Parental Approach to the Prevention and Management of Fever and Pain Following Childhood Immunizations: A Survey Study. <i>Clinical Pediatrics</i> , 2017 , 56, 435-442	1.2	6
114	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017 , 21, 3681-3690	10.6	67
113	T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. <i>JCI Insight</i> , 2017 , 2,	9.9	93
112	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , 2017 , 12, e0179597	3.7	20
111	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017 , 13, e1006182	7.6	30
110	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. <i>Journal of Immunology</i> , 2016 , 197, 4663-4673	5.3	5
109	Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016 , 8, 336ra62	17.5	65
108	Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. <i>Science Immunology</i> , 2016 , 1, aag0851	28	82
107	A rhesus macaque model of Asian-lineage Zika virus infection. <i>Nature Communications</i> , 2016 , 7, 12204	17.4	289
106	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. <i>Nature Medicine</i> , 2016 , 22, 1465-1469	50.5	73
105	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016 , 12, 196-207	8.8	28
104	Effect of antipyretic analgesics on immune responses to vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 2391-402	4.4	36
103	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. <i>Journal of Virology</i> , 2016 , 90, 5031-5046	6.6	27
102	Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 171-80	7.4	11
101	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016 , 165, 449-63	56.2	209

100	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016 , 90, 4951-4965	6.6	21
99	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016 , 14, 43-54	10.6	45
98	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. <i>JCI Insight</i> , 2016 , 1, e88522	9.9	6
97	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. <i>PLoS Pathogens</i> , 2016 , 12, e1005817	7.6	89
96	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. <i>Cell Reports</i> , 2016 , 15, 1505-157	1 3 0.6	21
95	HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015 , 349, aab1253	33.3	144
94	Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. <i>Journal of Infectious Diseases</i> , 2015 , 211, 508-17	7	44
93	Viral receptor-binding site antibodies with diverse germline origins. <i>Cell</i> , 2015 , 161, 1026-1034	56.2	114
92	Eliminating antibody polyreactivity through addition of N-linked glycosylation. <i>Protein Science</i> , 2015 , 24, 1019-30	6.3	8
91	Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. <i>Journal of Virology</i> , 2015 , 89, 9485-98	6.6	5
90	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015 , 18, 354-62	23.4	53
89	Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. <i>Proteins: Structure, Function and Bioinformatics</i> , 2015 , 83, 771-8	04.2	24
88	Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women. <i>Mucosal Immunology</i> , 2015 , 8, 316-26	9.2	18
87	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. <i>Cell Reports</i> , 2015 , 13, 2842-50	10.6	43
86	Antibodies for prevention of mother-to-child transmission of HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 177-82	4.2	6
85	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , 2015 , 7, 5443-75	6.2	20
84	Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. Journal of Clinical Investigation, 2015 , 125, 4077-90	15.9	104
83	A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infectious Diseases 2015, 15, 479	4	67

(2014-2015)

82	Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. Journal of Clinical Investigation, 2015 , 125, 2702-6	15.9	56
81	Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. <i>Cell Host and Microbe</i> , 2014 , 16, 304-13	23.4	99
8o	Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. <i>Journal of Virology</i> , 2014 , 88, 3329-39	6.6	64
79	Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. <i>Cell Host and Microbe</i> , 2014 , 16, 105-14	23.4	192
78	CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. <i>Journal of Virology</i> , 2014 , 88, 6542-55	6.6	40
77	HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. <i>Cell Host and Microbe</i> , 2014 , 16, 215-226	23.4	81
76	Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. <i>Cell</i> , 2014 , 158, 481	-9 6.2	213
75	Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. <i>Journal of Immunological Methods</i> , 2014 , 409, 99-106	2.5	21
74	HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. <i>PLoS ONE</i> , 2014 , 9, e101863	3.7	26
73	Progress in HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 134, 3-10; quiz 11	11.5	49
7 ²	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. <i>Frontiers in Immunology</i> , 2014 , 5, 170	8.4	77
71	Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. <i>Journal of Virology</i> , 2014 , 88, 5165-70	6.6	34
7°	HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. <i>Journal of Virology</i> , 2014 , 88, 7715-26	6.6	140
69	Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. <i>Immunity</i> , 2014 , 41, 909-18	32.3	50
68	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAXII B/E in RV144 Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A36-A36	1.6	1
67	Modulation of HIV-1 immunity by adjuvants. Current Opinion in HIV and AIDS, 2014, 9, 242-9	4.2	6
66	Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. <i>Journal of Immunology</i> , 2014 , 192, 3269-79	5.3	10
65	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1835-43	15.9	71

64	Influence of HLA-C expression level on HIV control. <i>Science</i> , 2013 , 340, 87-91	33.3	277
63	Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. <i>Immunity</i> , 2013 , 38, 176-86	32.3	319
62	Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. <i>Journal of Virology</i> , 2013 , 87, 7828-36	6.6	53
61	The human fetal lymphocyte lineage: identification by CD27 and LIN28B expression in B cell progenitors. <i>Journal of Leukocyte Biology</i> , 2013 , 94, 991-1001	6.5	21
60	Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. <i>Journal of Virology</i> , 2013 , 87, 11121-34	6.6	10
59	Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies. <i>Journal of Virology</i> , 2013 , 87, 13936-13936	6.6	78
58	HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. <i>Mucosal Immunology</i> , 2013 , 6, 692-703	9.2	62
57	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 9019-24	11.5	301
56	Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 264-9	11.5	170
55	Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. <i>Current HIV Research</i> , 2013 , 11, 378-87	1.3	69
54	Microbial Vaccine Development 2013 , 1119-1128		
53	Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. <i>Retrovirology</i> , 2012 , 9, 89	3.6	40
52	HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. <i>Trends in Microbiology</i> , 2012 , 20, 532-9	12.4	54
51	Antibody lineages with evidence of somatic hypermutation persisting for >4 years in a South African subject with broad neutralizing activity. <i>Retrovirology</i> , 2012 , 9,	3.6	78
50	Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject. <i>Retrovirology</i> , 2012 , 9,	3.6	78
49	Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes. <i>Retrovirology</i> , 2012 , 9,	3.6	78
48	Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum. <i>PLoS ONE</i> , 2012 , 7, e37648	3.7	25
47	Simultaneous Detection of Antigen-Specific IgG- and IgM-Secreting Cells with a B Cell Fluorospot Assay. <i>Cells</i> , 2012 , 1, 15-26	7.9	1

(2010-2012)

46	Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer. <i>Human Antibodies</i> , 2012 , 21, 65-73	1.3	4
45	Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. <i>Journal of Infectious Diseases</i> , 2012 , 206, 431-41	7	229
44	Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. <i>Journal of Virology</i> , 2012 , 86, 1152	21-32	294
43	HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. <i>Journal of Virology</i> , 2012 , 86, 7496-507	6.6	67
42	A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. <i>Journal of Virology</i> , 2012 , 86, 6979-85	6.6	112
41	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. <i>Journal of Virology</i> , 2011 , 85, 9998-10009	6.6	342
40	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. <i>Journal of Experimental Medicine</i> , 2011 , 208, 2237-49	16.6	166
39	Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. <i>Journal of Virology</i> , 2011 , 85, 10669-81	6.6	43
38	B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. <i>Trends in Molecular Medicine</i> , 2011 , 17, 108-16	11.5	35
37	H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. <i>PLoS ONE</i> , 2011 , 6, e25797	3.7	139
36	An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. <i>Journal of Virology</i> , 2011 , 85, 7029-36	6.6	180
35	Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. <i>Current Opinion in Immunology</i> , 2011 , 23, 383-90	7.8	79
34	Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 14216-21	11.5	331
33	Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. <i>Journal of Virology</i> , 2011 , 85, 11401-8	6.6	75
32	Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. <i>Journal of Virology</i> , 2011 , 85, 7719-29	6.6	50
31	Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. <i>PLoS ONE</i> , 2011 , 6, e23532	3.7	123
30	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. <i>Journal of Experimental Medicine</i> , 2010 , 207, 763-76	16.6	48
29	The humoral response to HIV-1: new insights, renewed focus. <i>Journal of Infectious Diseases</i> , 2010 , 202 Suppl 2, S315-22	7	38

28	Necrotizing fasciitis caused by Haemophilus influenzae type E in a 17-year-old girl with systemic lupus erythematosus. <i>Journal of Clinical Rheumatology</i> , 2010 , 16, 49-50	1.1	6
27	HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. <i>Journal of Immunology</i> , 2009 , 183, 2708-17	5.3	58
26	Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. <i>PLoS Medicine</i> , 2009 , 6, e1000107	11.6	129
25	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. <i>Journal of Virological Methods</i> , 2009 , 158, 171-9	2.6	181
24	Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. <i>Virology</i> , 2009 , 394, 91-8	3.6	27
23	Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. <i>PLoS ONE</i> , 2009 , 4, e7215	3.7	20
22	Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. <i>Journal of Virology</i> , 2008 , 82, 115-25	6.6	101
21	Antigen-specific B cell detection reagents: use and quality control. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2008 , 73, 1086-92	4.6	24
20	Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. <i>Journal of Virology</i> , 2008 , 82, 7700-10	6.6	64
19	Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. <i>Pediatric Infectious Disease Journal</i> , 2008 , 27, 1047-51	3.4	75
18	Polychromatic plots: graphical display of multidimensional data. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2008 , 73, 868-74	4.6	11
17	Predictive value of cerebrospinal fluid parameters in neonates with intraventricular drainage devices. <i>Journal of Neurosurgery: Pediatrics</i> , 2007 , 107, 209-12	2.1	13
16	Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters?. <i>Pediatrics</i> , 2006 , 117, 1094-100	7.4	239
15	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. <i>Human Antibodies</i> , 2006 , 14, 59-67	1.3	120
14	A comparison of neonatal Gram-negative rod and Gram-positive cocci meningitis. <i>Journal of Perinatology</i> , 2006 , 26, 111-4	3.1	25
13	Antibody polyspecificity and neutralization of HIV-1: a hypothesis. <i>Human Antibodies</i> , 2005 , 14, 59-67	1.3	103
12	Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. <i>Molecular Genetics and Metabolism</i> , 2003 , 78, 291-4	3.7	8
11	Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies. <i>Journal of Virology</i> , 1999 , 73, 746-50	6.6	11

LIST OF PUBLICATIONS

10	The PIG-A Mutation and Absence of Glycosylphosphatidylinositol-Linked Proteins Do Not Confer Resistance to Apoptosis in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 1998 , 92, 2541-2550	2.2	49
9	The PIG-A Mutation and Absence of Glycosylphosphatidylinositol-Linked Proteins Do Not Confer Resistance to Apoptosis in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 1998 , 92, 2541-2550	2.2	2
8	Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF. <i>Biochemistry</i> , 1996 , 35, 5158-65	3.2	32
7	HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. <i>AIDS Research and Human Retroviruses</i> , 1995 , 11, 211-21	1.6	18
6	NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus. <i>Biochemistry</i> , 1994 , 33, 2055-62	3.2	42
5	Allylic substitution/rearrangement of cannabinoids with trimethylsilyl bromide. <i>Tetrahedron Letters</i> , 1992 , 33, 3443-3446	2	6
4	Pyrrole oxidation and protein cross-linking as necessary steps in the development of gamma-diketone neuropathy. <i>Chemical Research in Toxicology</i> , 1988 , 1, 179-85	4	76
3	Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth		1
2	Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macad	ques	4
1	Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity		1